Division of Rheumatology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
Philip R. Lee Institute for Health Policy Research, San Francisco, USA.
Arthritis Res Ther. 2021 Aug 30;23(1):224. doi: 10.1186/s13075-021-02615-7.
Behçet's disease (BD), a chronic systemic vasculitis, has distinct geographical and ethnic variation. Data regarding the epidemiology of patients with BD in the U.S. are limited; therefore, we sought to describe BD patient characteristics and medication use in the U.S., and compared them with data from patients from endemic regions.
We conducted a cross-sectional study using data from the RISE registry (2014-2018). Patients aged ≥ 18 years with BD were included. Sociodemographic and treatment information was extracted. We compared patients from the RISE registry to data from other published studies of patients with BD from endemic areas.
One thousand three hundred twenty-three subjects with BD from the RISE registry were included. Mean age was 48.7 ± 16.3 years, female to male ratio was 3.8:1, and 66.7% were White. The most frequently used medications included glucocorticoids (67.6%) and colchicine (55.0%). Infliximab and adalimumab were the most used biologics (14.5% and 14.1%, respectively); 3.2% of patients used apremilast. The RISE registry had more women (79.3%), and patients were older compared to previously published BD studies from endemic areas. Methotrexate and TNFi were more commonly reported in RISE (21.8% and 29.4%) compared to studies from Egypt and Turkey. Colchicine, cyclosporine, and cyclophosphamide were more commonly used in cohorts from Egypt, Turkey, and Iran.
Findings from the largest BD dataset in the U.S. suggest that BD patients are predominantly female. Further research is needed to explore the reasons for the higher prevalence of BD among women in the U.S. and its possible impact on disease severity and management.
贝赫切特病（BD）是一种慢性系统性血管炎，具有明显的地域和种族差异。美国有关 BD 患者流行病学的数据有限；因此，我们旨在描述美国 BD 患者的特征和药物使用情况，并将其与来自流行地区的患者数据进行比较。
我们使用 RISE 登记处（2014-2018 年）的数据进行了一项横断面研究。纳入年龄≥18 岁的 BD 患者。提取社会人口统计学和治疗信息。我们将 RISE 登记处的患者与其他来自流行地区的 BD 患者发表研究的数据进行了比较。
RISE 登记处的 1323 名 BD 患者包括在内。平均年龄为 48.7±16.3 岁，女性与男性比例为 3.8:1，66.7%为白人。最常使用的药物包括糖皮质激素（67.6%）和秋水仙碱（55.0%）。英夫利昔单抗和阿达木单抗是最常用的生物制剂（分别为 14.5%和 14.1%）；3.2%的患者使用阿普米司特。与先前发表的来自流行地区的 BD 研究相比，RISE 登记处的女性更多（79.3%），且患者年龄更大。与来自埃及和土耳其的研究相比，RISE 中报告的甲氨蝶呤和 TNFi 更为常见（分别为 21.8%和 29.4%）。秋水仙碱、环孢素和环磷酰胺在来自埃及、土耳其和伊朗的队列中更为常用。
美国最大的 BD 数据集的结果表明，BD 患者主要为女性。需要进一步研究来探讨美国女性中 BD 患病率较高的原因及其对疾病严重程度和管理的可能影响。
